# Collegium Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/collegium-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.collegiumpharma.com
- Total disclosed funding: $109M
- Latest round: Series D (Mar 10, 2015)
- Investors on record: 12

## About

Collegium Pharmaceutical is a biopharmaceutical company focused on the development and commercialization of innovative medications for pain management and treatment of serious medical conditions.Collegium Pharmaceutical, Inc. was founded in 2002 in the United States and specializes in developing unique pharmaceutical solutions. The company has undergone significant growth, raising USD 55.00 mn in a PRIVATE PLACEMENT/FOLLOW ON in 2015. Joe Ciaffoni and Michael Heffernan serve as CEO. Collegium's headquarters are located in the United States, and the company has completed a total of 12 deals to date.Collegium Pharmaceutical specializes in developing and commercializing differentiated medications aimed at treating serious medical conditions. Their primary focus is on pain management, offering proprietary formulations designed to address chronic pain and other serious ailments. The company serves healthcare professionals and patients, ensuring access to their therapeutic solutions through established sales channels.In 2024, Collegium Pharmaceutical reported a revenue of USD 631.45 mn with an EBITDA of USD 339.06 mn. The company generates income through direct sales to healthcare providers and partnerships with wholesalers, ensuring that licensed U.S. healthcare professionals can prescribe their products effectively.Collegium Pharmaceutical plans to release several new products targeting significant unmet medical needs in pain management, with further details expected by mid-2025. The company aims to expand into international markets, particularly in Europe and Asia, by 2026, leveraging its recent funding from the USD 55.00 mn Private Placement/Follow On to support research and development efforts and market entry strategies.

## Funding rounds

- Series D, Mar 10, 2015, $50M — Boston Millennia Partners, Frazier Healthcare Partners, Skyline Ventures, Aperture Venture Partners, Adage Capital Management, Longitude Capital, TPG Biotech, RA Capital Management, EcoR1 Capital, Rock Springs Capital, Eventide Asset Management
- Series C, Dec 4, 2013, $4M — Frazier Healthcare Partners, Skyline Ventures
- Series C, Sep 25, 2013, $4M — Frazier Healthcare Partners
- Series B, Feb 22, 2012, $23M — Boston Millennia Partners, Frazier Healthcare Partners, Skyline Ventures, Longitude Capital
- Series D, Jul 15, 2008, $20M — Boston Millennia Partners, Frazier Healthcare Partners, Westfield Capital Management
- Series C, Oct 15, 2006, $5.5M — Boston Millennia Partners, Westfield Capital Management
- Series A, Oct 28, 2003, $3M — Boston Millennia Partners

## Investors

- Boston Millennia Partners (https://capitalatlas.ai/funds/boston-millennia-partners) — Series A, Series C, Series D, Series B
- Westfield Capital Management (https://capitalatlas.ai/funds/westfield-capital-management) — Series C, Series D
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series D, Series B, Series C
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series B, Series C, Series D
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series B, Series D
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series D
- Adage Capital Management — Series D
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series D
- Rock Springs Capital — Series D
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series D